What does PERJETA treat?
PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel (chemotherapy) in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
Important Safety Information
- PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure)
- Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects
- If you think you may be pregnant, you should contact your healthcare provider immediately
- If you are exposed to PERJETA during pregnancy, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720
- PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA
- Other possible serious side effects of PERJETA therapy include:
- Infusion-related reactions
- Severe allergic reactions (hypersensitivity reactions/anaphylaxis)
- PERJETA has only been shown to work in people with HER2-positive breast cancer
- The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) for treatment of breast cancer that has spread to other parts of the body (metastatic) are:
- Hair loss
- Low levels of white blood cells with or without a fever
- Feeling tired
- Damage to the nerves (numbness, tingling, pain in hands/feet)
You are encouraged to report side effects to Genentech or the FDA. You may report side effects to the FDA at 1-800-FDA‐1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see PERJETA full Prescribing Information including Most Serious Side Effect for additional Important Safety Information.
PERJETA® and the Access Solutions logo are registered trademarks of Genentech, Inc.